About
DeStrain is a specialized digital therapeutics program developed by Bynocs, a globally patented and clinically validated platform for binocular vision disorders. Specifically targeting Computer Vision Syndrome (CVS)—also known as asthenopia or digital eye strain—DeStrain delivers structured, AI-guided vision therapy sessions through a cloud-based interface accessible to both patients and healthcare providers. Built on Bynocs' proprietary dichoptic digital therapy technology, DeStrain presents distinct visual stimuli to each eye independently, retraining the visual system to reduce strain, headaches, blurred vision, and other CVS symptoms associated with prolonged screen exposure. The program is part of a broader suite of vision therapy tools that also addresses amblyopia (lazy eye) and intermittent squint. DeStrain is designed for a wide audience: office workers, students, and anyone who spends extended hours in front of digital screens, as well as optometrists and ophthalmologists looking for evidence-based therapeutic tools for their patients. The platform features dedicated portals for patients and doctors, enabling clinical oversight, progress tracking, and remote therapy management. With a presence across Asia Pacific, Europe, North America, Africa, the Middle East, and Latin America, Bynocs serves a global user base through its SaaS delivery model. A free demo is available for new users, allowing clinicians and patients to experience the therapy before committing to a full plan. DeStrain stands out as a non-invasive, software-first solution for a condition affecting millions of screen users globally.
Key Features
- Dichoptic Digital Therapy: Delivers distinct visual stimuli to each eye independently, retraining the visual system to alleviate digital eye strain symptoms.
- AI-Powered Treatment Programs: Uses artificial intelligence to personalize and adapt vision therapy sessions based on each patient's progress and condition severity.
- Cloud-Based Patient & Doctor Portals: Separate dedicated dashboards for patients and eye care professionals enable remote monitoring, progress tracking, and clinical management.
- Clinically Validated & Globally Patented: Backed by clinical research and protected by global patents, ensuring evidence-based, safe, and effective therapy outcomes.
- Multi-Condition Vision Therapy Suite: Part of the broader Bynocs platform addressing amblyopia, intermittent squint, and digital eye strain under one unified system.
Use Cases
- Office workers and remote employees experiencing eye fatigue, headaches, or blurred vision from extended computer use seeking a non-invasive treatment option.
- Students with heavy daily screen time who suffer from recurring digital eye strain symptoms and need structured, clinically backed therapy.
- Optometrists and ophthalmologists looking to integrate evidence-based digital therapeutics into their practice for Computer Vision Syndrome patients.
- Corporate wellness programs aiming to reduce productivity loss caused by digital eye strain among their screen-heavy workforce.
- Eye care clinics offering remote or telehealth vision therapy services who need a cloud-based platform to manage and monitor patient progress.
Pros
- Clinically Proven Efficacy: Backed by clinical validation and globally patented technology, providing confidence in the therapeutic outcomes for both patients and practitioners.
- Accessible Cloud-Based Platform: Being fully cloud-based means patients can undergo therapy from home while doctors monitor progress remotely, removing geographic barriers.
- Free Demo Available: A no-commitment free demo allows patients and clinicians to evaluate the therapy before purchasing, lowering the barrier to entry.
- Global Reach & Multi-Language Support: Supported across six major global regions with dedicated regional contact teams, making it suitable for international clinical practices.
Cons
- Requires Professional Oversight: The platform is designed for use under the guidance of an eye care professional, which may limit purely self-directed consumer adoption.
- Narrow Application Domain: Focused exclusively on binocular vision disorders, so it has limited utility outside of ophthalmic or optometric clinical contexts.
- Pricing Not Publicly Listed: Full subscription pricing is not transparently displayed on the website, requiring users to request a demo or contact sales for details.
Frequently Asked Questions
What is Computer Vision Syndrome (CVS)?
Computer Vision Syndrome, also called digital eye strain or asthenopia, is a group of eye and vision-related problems caused by prolonged use of digital screens. Symptoms include eye fatigue, headaches, blurred vision, dry eyes, and neck or shoulder pain.
How does DeStrain Therapy work?
DeStrain uses proprietary dichoptic digital therapy, which presents different visual stimuli to each eye simultaneously. This targeted approach retrains the visual system to reduce the strain and discomfort associated with long-term screen exposure.
Is DeStrain clinically validated?
Yes. DeStrain by Bynocs is a clinically validated and globally patented therapy. It has been tested in clinical settings and shown to improve outcomes for patients suffering from digital eye strain and other binocular vision disorders.
Who is DeStrain designed for?
DeStrain is designed for patients experiencing digital eye strain—including office workers, students, and heavy screen users—as well as for optometrists and ophthalmologists who want to offer evidence-based vision therapy to their patients.
How can I get started with DeStrain?
You can start with a free demo by visiting the Bynocs website and clicking the 'Free Demo' button. A representative from your regional Bynocs team will guide you through the onboarding process and help determine the right therapy plan.
